Semax

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) studied in the scientific literature as an analog of the ACTH(4-10) fragment of adrenocorticotropic hormone. It is sold by Certified Aminos strictly for laboratory research use; no clinical or commercial testing claims are made about this specific product.

Semax is a synthetic analog modeled on ACTH(4-10), a fragment of adrenocorticotropic hormone that lies outside the region of the hormone primarily responsible for its adrenal-stimulating (steroidogenic) activity. Published studies report no meaningful adrenocortical activity for this class of ACTH(4-10) analog; this is a structural and pharmacological distinction, not a claim about Semax’s clinical effects.

They are different molecules: Semax is Met-Glu-His-Phe-Pro-Gly-Pro, an ACTH-fragment analog; Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a tuftsin analog. A vendor-cited in-vitro human-serum assay describes both peptides inhibiting enkephalin-degrading enzymes, with Semax reported as more potent than Selank -- the specific potency figures behind that comparison could not be independently confirmed against a located primary source, so they are omitted here pending verification. Either way, this describes an isolated enzyme-inhibition assay, not a confirmed mechanism of action in living humans, and it is a separate evidence record for each peptide even though both were reportedly tested in the same study.

No, but the exact chemical difference should be checked against a primary source rather than assumed. Vendor and forum sources describe 'N-Acetyl Semax' as carrying N-terminal acetylation and C-terminal amidation relative to unmodified Semax, but naming is applied inconsistently across suppliers and this description was not confirmed against a peer-reviewed or chemical-database source. Findings on one of these peptides should not be assumed to apply to the other.

Primarily rodent studies (behavioral, neurochemical, and ischemia models), including work on hippocampal BDNF/TrkB signaling and striatal serotonergic activity. A smaller set of published studies also describe clinical use of a Semax-based pharmaceutical formulation in Russia for stroke-related indications. That formulation's manufacturing, dosing, and regulatory status in Russia are separate from, and establish nothing about, the research-grade material Certified Aminos sells.

As hypotheses with mixed, mostly preclinical support, not settled pharmacology. Reported mechanisms include BDNF/TrkB upregulation (animal studies), modulation of striatal serotonergic activity (animal studies), and inhibition of enkephalin-degrading enzymes (an in-vitro human-serum assay, with specific potency figures unconfirmed by us). None of these has been shown to establish a clinical outcome, and none describes the Certified Aminos product specifically.

It means the product is sold and intended solely for laboratory and research applications, not for human or veterinary consumption, self-administration, diagnosis, treatment, prevention of disease, or cosmetic use of any kind.

A proper COA documents the testing performed on a specific batch, typically identity confirmation and a purity percentage, tied to a lot number and an identifiable testing method for that batch. It does not by itself confirm sterility, biological activity, or long-term stability, and Certified Aminos has not published a linkable COA file for Semax as of this review.

HPLC reports relative purity based on peak area; mass spectrometry (or amino-acid sequencing) confirms molecular identity. Not every COA includes both methods, so buyers should check which tests a specific document actually reports rather than assuming a standard panel; neither test establishes safety or efficacy.

Format, exact concentration, a batch-matched COA with stated testing methodology, storage requirements, and the seller's RUO and shipping terms. Buyers should request this documentation directly from Certified Aminos for the specific lot they intend to purchase.